IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v6y2022i6d10.1007_s41669-022-00365-z.html
   My bibliography  Save this article

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

Author

Listed:
  • Andrew Blauvelt

    (Oregon Medical Research Center)

  • Nianwen Shi

    (IBM Watson Health)

  • Russel Burge

    (Eli Lilly and Company
    University of Cincinnati)

  • Bilal Atiya

    (Eli Lilly and Company)

  • Baojin Zhu

    (Eli Lilly and Company)

  • Najwa Somani

    (Eli Lilly and Company)

  • Terri Ridenour

    (Eli Lilly and Company)

  • Carolyn R. Lew

    (IBM Watson Health)

  • Nicole M. Zimmerman

    (IBM Watson Health)

  • Mwangi J. Murage

    (Eli Lilly and Company)

Abstract

Objective The aim of this study was to compare healthcare costs between ixekizumab (IXE)-treated and secukinumab (SEC)-treated patients with psoriasis over a 24-month follow-up period in the United States. Methods Patients with psoriasis diagnosis were identified from IBM Watson Health MarketScan® Research Databases; those with one or more claim for index drug (IXE or SEC) between March 1, 2016 and October 31, 2019 were included. Included patients were ≥ 18 years old and had continuous enrollment with medical and pharmacy benefits ≥ 6 months before and ≥ 24 months after index date. Patients were classified as IXE or SEC users based on drug received at index. Per patient per month (PPPM) all-cause, psoriasis-related, and index drug costs for IXE and SEC users were estimated over 24 months of follow-up. Institute for Clinical and Economic Review (ICER) discount factors were applied to adjust pharmacy costs. Index drug costs were additionally adjusted for adherence. Inverse probability of treatment weighting was used to address cohort imbalances. Chi-square/t tests were used to compare IXE versus SEC users; p value

Suggested Citation

  • Andrew Blauvelt & Nianwen Shi & Russel Burge & Bilal Atiya & Baojin Zhu & Najwa Somani & Terri Ridenour & Carolyn R. Lew & Nicole M. Zimmerman & Mwangi J. Murage, 2022. "Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months," PharmacoEconomics - Open, Springer, vol. 6(6), pages 871-880, November.
    • Handle: RePEc:spr:pharmo:v:6:y:2022:i:6:d:10.1007_s41669-022-00365-z
    DOI: 10.1007/s41669-022-00365-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-022-00365-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-022-00365-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:6:y:2022:i:6:d:10.1007_s41669-022-00365-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.